ArticleExperimental and therapeutic medicine2018

Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-κB signaling pathway.

Yi-Jiong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.